Educated Patient® Multiple Myeloma Summit: March 13, 2021

Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.

Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.

Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.

Dr. Hope S. Rugo explains what KEYNOTE-B49 found about adding Keytruda to chemotherapy for PD-L1-positive, HR-positive, HER2-negative breast cancer.

Three phase 3 prostate cancer results from ESMO 2026 cover long-term survival with abiraterone in metastatic disease, Erleada before and after surgery, and an update on Truqap for PTEN-deficient cancer.

Longer follow-up presented at the 2026 ESMO Congress showed that four already-approved treatments for early breast cancer, kidney cancer, colorectal cancer and stomach and esophageal cancer kept helping patients years later.